To identify additional druggable vulnerabilities to set the stage for more effective combination therapies in FGFR1-dependent cancer, Singleton et al. [92] deployed kinome-targeting shRNA libraries to screen for protein kinase pathways that would significantly increase sensitivity to FGFR-specific TKIs. The gene discussed is FGFR1; the disease is cancer.